Abivax annual return on equity
2022
2023
2024
2025
Abivax Return on Equity (ROE) Growth & History (ABVX)
Abivax's return on equity was −135.58% for fiscal 2025.
View full Abivax company overviewAbivax annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −135.58% | +13.40 pp |
| 2024 | 2024-12-31 | −148.98% | −3.57 pp |
| 2023 | 2023-12-31 | −145.41% | +221.34 pp |
| 2022 | 2022-12-31 | −366.75% | — |
Abivax quarterly return on equity
Q4.24
Q1.25
Q3.25
Q4.25
Q1.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q1 2026 | 2026-03-31 | −10.96% | +297.18 pp |
| Q4 2025 | 2025-12-31 | −16.96% | +16.33 pp |
| Q3 2025 | 2025-09-30 | −66.25% | — |
| Q1 2025 | 2025-03-31 | −308.13% | — |
| Q4 2024 | 2024-12-31 | −33.29% | — |
Abivax return on equity trends
Between the periods ended 2022-12-31 and 2025-12-31, Abivax's return on equity increased from −366.75% to −135.58%, a change of +231.17 percentage points. The latest reported quarter, Q1 2026, shows −10.96%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Abivax source filings ↗